Can I read P445 Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab on EtoBox?

P445 Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab by C Miller; H Kwok; I Parisi; P Harrow; S McCartney; R Vega; F Rahman; E Seward; S Mehta; S Lim; E Sharma; M Samaan; A Bancil; K Kok; A Shalabi; E Johnston; D Katarey; N Taherzadeh; C Murray; M Sharip; M Carter; S Radhakrishnan; S Peake; I Khakoo; M Wahed; S Povlsen; M Patel; P Dubois; J Finkel; C Onnie; S Bloom is a Medicine article available to read on EtoBox.

What is P445 Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab about?

## Abstract ## Background Drug choice and order in Inflammatory Bowel Disease (IBD) is an important challenge and is becoming increasingly complex. There are few studies comparing head-to-head outcomes in second line treatments in Ulcerative Colitis (UC). It is unclear if using anti-Tumour Necrosis Factor-a (anti-TNF) therapy following vedolizumab (VDZ) or VDZ after anti-TNF has a more favourable outcome in UC in a real-world outpatient setting. ## Methods Patients with UC who were exposed to first-line anti-TNF (adalimumab/ADA or infliximab/IFX) or VDZ who subsequently switched to the alternate class between May 2013-August 2020 were identified following a review of databases at 10 hospitals. 88 VDZ and 39 anti-TNF (12 ADA,27 IFX) second line patients were eligible. Data was collected retrospectively. Baseline demographics, disease activity indices, colectomy rates, treatment persistence and healthcare resource utilisation composite endpoint (HRUC) were examined over a 52 week period for the second line biologic. HRUC included unplanned emergency hospital attendance or hospital admission. The primary endpoints of 52 week treatment persistence, HRUC survival and colectomy free surv

Who reads P445 Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab?

Author

C Miller; H Kwok; I Parisi; P Harrow; S McCartney; R Vega; F Rahman; E Seward; S Mehta; S Lim; E Sharma; M Samaan; A Bancil; K Kok; A Shalabi; E Johnston; D Katarey; N Taherzadeh; C Murray; M Sharip; M Carter; S Radhakrishnan; S Peake; I Khakoo; M Wahed; S Povlsen; M Patel; P Dubois; J Finkel; C Onnie; S Bloom

Publisher

Oxford University Press (OUP)

Published

2021

Language

EN

Field

Medicine (Health Sciences)